Introduction
Acute myeloid leukemia (AML) is defined morphologically by an abnormal increase in myeloblasts in the bone marrow (BM). Since they are heterogeneous in morphologic and cytogenetic features, their prognoses are extremely variable. Early studies showed that irrespective of the morphologic subtypes, only a small fraction of leukemic cells, the putative leukemic stem cells (LSC), can recapitulate the leukemia when injected into sublethally irradiated NOD/SCID mice. 1 LSC may be derived from the neoplastic transformation of normal hematopoietic stem cells (HSC); therefore, they share stem cell features of replicative quiescence and self-renewal potential. Intensive chemotherapy in AML targets divide leukemic blasts, but may not be effective for LSC that are quiescent in cell cycling. Hence, therapy directed at LSC for preventing late relapses is an important prospect in antileukemia therapy. 2 Like HSC, LSC are enriched in the CD34 þ CD38 À fraction of the AML cells 1, 3 Further studies have refined the LSC phenotype as CD34 þ CD38 À CD90 À CD117 À , in contrast to HSC, which are mostly CD34 þ CD38 À CD90 þ CD117 þ . 4, 5 Furthermore, leukemic cells bearing HSC phenotypes are dissimilar functionally, and only a small fraction of them contains LSC. Discordant results have also been reported in which LSC may be CD34 þ CD90 þ or even CD34 À . 4, 6, 7 Therefore, surface immunophenotype alone may not reliably define LSC.
Aldehyde dehydrogenase (ALDH) is a family of enzymes involved in the metabolism of aldehydes to their corresponding carboxylic acids. In liver, cytosolic ALDH1A1 (referred herein as ALDH) contributes primarily to the biosynthesis of retinoic acid from retinol (vitamin A). It is also highly expressed in human and murine hematopoietic stem and progenitor cells. [8] [9] [10] [11] [12] [13] In particular, CD34
þ ALDH bright (ALDH br ) cells from human umbilical cord blood (UCB) have been shown to contain all the NOD/SCID engrafting cells in the CD34 þ cells. 11 Furthermore, in mobilized peripheral blood stem cells (PBSC), the side-scatter low ALDH br (SSC lo ALDH br ) cells are highly enriched for human HSC. 13 Furthermore, ALDH correlated positively with the capability of PBSC graft in hematopoietic reconstitution during HSC transplantation (HSCT). 10 The functional role of ALDH was demonstrated recently, in which diethylaminobenzaldehyde (DEAB), a specific inhibitor of ALDH, deregulated human HSC self renewal by interfering with endogenous retinoic acid biosynthesis.
14 These data suggested that ALDH may regulate HSC function and is a potential therapeutic target. Therefore, in the present study, we investigated the ALDH activity in bone marrow samples from healthy donors and leukemia patients, and examined its link with LSC.
Materials and methods

BM samples collection and processing
BM samples were prospectively collected from patients with acute myeloid and lymphoblastic leukemia (AML and ALL)
at presentation or at frank relapse. In all cases, they were independently reviewed and reported by hematopathologists who were unaware of the study protocols and results. The myeloid lineage differentiation of all AML cases has been confirmed by positive myeloperoxidase and/or Sudan Black B cytochemical staining. Control BM samples were also obtained from normal BM donors for HSCT. Mononuclear cells (MNC) were purified by density gradient centrifugation (Ficoll-Paque Plus, Amersham Biosciences, Uppsala, Sweden) and stored in liquid nitrogen until use. CD34 þ cells were isolated from MNC by immunomagnetic methods (Miltenyi, Bergisch Gladbach, Germany) with over 95% purity after double-column selection. The investigation has been approved by the institution review board in accordance with the Declaration of Helsinki.
Aldefluor assay and flow cytometry ALDH activity was enumerated in MNC as per manufacturer's instruction (Aldefluor, STEMCO Biomedical Inc., CA, USA). In some experiments, the cells were costained with phycoerythrin (PE)-conjugated anti-CD34 antibody (clone 8G12, BD BioSciences, CA, USA). Stained samples were then analyzed by flow cytometry (Cytomics FC500 MPL flow cytometry system, Beckman Coulter, Fullerton, CA, USA). cells/dose) were transplanted into sublethally irradiated (300 cGy) NOD/SCID mice (NOD.CB17-Prkdc scid /J from Jackson Lab Maine, USA), 6-8 weeks old, intrafemorally into the right femur. 15 In six cases, MNC was injected. Recipient mice were killed at 6-8 weeks after transplantation and BM were 
NOD/SCID transplantation
Clonality of engrafted leukemic cells
Clonality of engrafting leukemic cells was analyzed based on known cytogenetic abnormality at presentation by fluorescence in situ hybridization (FISH) or reverse transcriptase (RT)-PCR whenever available. Detection of À7, þ 8 and þ 11 chromosomal aberrations in the leukemic human cells were performed using CEP 7 (D7Z1) alpha satellite DNA probe, CEP 8 (D8Z2) alpha satellite DNA probe and LSI MLL dual color, break apart rearrangement probes (Vysis, Downer's Grove, IL, USA) in three ALDH þ AML patients, respectively, according to the manufacturer's instructions. In total, 500 interphase nuclei on cytospin smears were analyzed for the presence of numerical changes. RT-PCR was carried out using the N1/H1 and N2/H2 primer sequences for NUP98/HOXA9 fusion as described. 16 Protocols related to flow cytometry, RT-PCR and immunohistochemistry for ALDH as well as detection of Flt3 internal tandem duplication (ITD) were submitted in Supplementary Information.
Statistical evaluation
Comparisons between groups of data were evaluated by the Mann-Whitney U-test (continuous data) and Pearson's w 2 -test (categorical data). P-value less than 0.05 was considered statistically significant.
Results
Patient characteristics
A total of 58 BM samples were prospectively collected and examined. There were 43 AML samples (32 at diagnoses (Figure 1 , Tables 1 and 2 ).
Clinicopathologic correlation
The clinicopathologic characteristics of ALDH þ and ALDH À AML were examined. There was no significant difference in morphologic subtypes, marrow blast percentage, CD34 expression and the presence of FLT3 internal tandem duplication (FLT3 ITD) between these two groups of AML. However, poor prognostic cytogenetic aberrations were significantly more frequent in ALDH þ AML, whereas those with good prognosis, particularly t(15;17) and t(8;21) were found exclusively in the ALDH À AML (Pearson's w 2 -test, P ¼ 0.006) ( Table 3) . Serial BM samples before and after intensive chemotherapy were available in five ALDH þ AML patients ( 
ALDH activity in AML was regulated at transcriptional level ALDH gene expression was next examined in the ALDH
þ and ALDH À samples. ALDH mRNA expression was significantly upregulated in ALDH þ as compared with ALDH À samples (Figure 2a) . ALDH protein expression between ALDH þ and ALDH À AML was examined by immunohistochemistry on trephine biopsies (Figure 2b-g ). ALDH staining (cytoplasmic) was observed only in ALDH þ (Figure 2b-d) but not in ALDH À AML (Figure 2e and f) . The ALDH þ cells had blast morphology and were located in the intertrabecular region. They also coexpressed CD34, confirming the results seen in flow cytometry (Figure 2d ). (Table 6 and Figure 3e-h ). FISH and RT-PCR studies confirmed that the engrafting human cells were derived from the transplanted AML clones (Figure 3i-l 6 /dose), only one mouse showed significant engraftment in both injected and uninjected marrow, and two other mice showed a marginally detectable (0.5-1%) human cell engraftment exclusively in the injected femur. (Table 5a and Figure 4 ) There was no significant difference in injected CD34 þ cell dose in the two groups of AML (P ¼ 0.48).
SSC
Discussions
Previous studies have demonstrated that ALDH is expressed in both human UCB and PBSC and that the SSC lo ALDH br population is highly enriched with HSC as enumerated by NOD/SCID repopulating assay. [9] [10] [11] [12] [13] In this study, we identified a similar but more robust SSC lo ALDH br population in BM samples from 14 out of 43 AML, but none of the eight ALL cases. Although detailed phenotypic characterization of these leukemia was not available, the myeloid lineage of the AML was confirmed by positive myeloperoxidase and/or Sudan black B 18 and sequence analysis of the ALDH promoter has also revealed sites potentially regulated by a number of putative leukemic genes (Supplementary Information). The mechanisms whereby individual ALDH þ AML upregulated ALDH expression remained to be elucidated. On the other hand, the low level of ALDH expression in ALDH À AML also raised the possibility that post-transcriptional regulation may be involved in determining ALDH activity in AML. This issue would have to be further examined.
Thirdly, we demonstrated that ALDH þ AML was significantly associated with cytogenetic changes of unfavorable prognosis. This was not observed in a previous study by Pearce et al. 17 This difference was due to the examination of a larger number of patients in the current study, as well as our more stringent gating strategy in which only the SSC lo fraction of the ALDH þ population was examined. In particular, cyotogenetic changes of inv(3), monosomy 7 and trisomy 8 were found exclusively in the ALDH þ AML whereas t(8;21) and t(15;17) were observed only in ALDH À AML. Expression of ALDH did not correlate with FLT3 ITD, a molecular abnormality identified in LSC and associated with adverse prognosis. 19 Moreover, the limiting number of patients recruited in this study and the variation of treatment received have precluded correlation between ALDH activity and actual clinical outcome of the patients.
A number of observations have remained unexplained. First, in spite of a link to LSC, the functional role of ALDH is presently unclear. Overexpression of ALDH in human and murine hematopoietic progenitor cells have resulted in resistance to cyclophosphamide (a substrate of ALDH). 20, 21 On the other hand, ALDH knockdown in lung cancer cell line by siRNA increased susceptibility to this agent. 22 The ALDH-specific inhibitor, DEAB, has more recently been shown to deregulate human HSC self renewal by interfering with endogenous retinoic acid biosynthesis.
14 Intriguingly, all-trans-retinoic acid may act directly on murine HSC to enhance their maintenance in cultures. 23 Whether ATRA may affect LSC in vivo would have to be further evaluated. Second, murine studies have demonstrated that the HSC niche might be located at the vicinity of spindle-shaped osteoblasts in the endosteal surface. 24 A leukemia niche has also been located in the trabecular endosteum. 25 In the present study, the leukemic niche could not be defined as most of the CD34 þ SSC lo ALDH br cells were interspersed in the intertrabecular area. Third, the overall NOD/ SCID engraftment levels in this study were lower than reported previously. 1 Whether this represented a difference in transplanted cell population or cell dose is presently unclear. Nonetheless, as both ALDH þ and ALDH À AML in this study were transplanted in similar fashion, a comparison between these populations remained to be useful in addressing the link between ALDH and LSC. Furthermore, the limited quantity of patient samples has precluded more stringent isolation of leukemia stem/progenitor cells by FACS sorting and, as a result, total CD34 þ cells were transplanted into NOD/SCID mice. Therefore, we could not exclude the contribution of engraftment by ALDH À cells in ALDH þ AML cases. Finally, as ALDH was expressed robustly in only 14 out of 43 AML cases, the identity of LSC in ALDH À AML should be critically evaluated in future studies.
The results of the present study may provide grounds for the future study of LSC and treatment of AML based on ALDH activity. In particular, the effect of DEAB on the engraftment potential of LSC should be critically evaluated. Furthermore, a comparison of gene expression and proteomic profiles between ALDH þ and ALDH À cells within the CD34 þ population may provide useful information on the regulatory mechanisms of ALDH expression and how this relates to LSC activity. 
